Immune checkpoint inhibitors (ICI) have been a major breakthrough in the treatment scenario of patients affected by solid cancers and haematological malignancies. First-line pembrolizumab, a programmed cell death -1 (PD-1) inhibitor, was recently shown to lead to a two-fold increase of overall survival rate in a subgroup of naïve non-small-cell lung cancer (NSCLC) patients when compared to chemotherapy [1]. However, ICI came together with the occurrence of unique clinical manifestations called immune-related adverse events (irAEs) [2,3].
